×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Myovant Sciences Stock Forecast, Price & News

$12.96
+0.53 (+4.26%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$12.27
$12.99
50-Day Range
$7.78
$13.77
52-Week Range
$7.67
$27.43
Volume
397,916 shs
Average Volume
805,586 shs
Market Capitalization
$1.24 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.67

Myovant Sciences Stock Forecast (MarketRank)

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
28.6% Upside
$16.67 Price Target
Short Interest
Healthy
10.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$192.08 K Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.45) to ($1.55) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.69 out of 5 stars

Medical Sector

936th out of 1,428 stocks

Pharmaceutical Preparations Industry

462nd out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive MYOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myovant Sciences and its competitors with MarketBeat's FREE daily newsletter.

Myovant Sciences logo

About Myovant Sciences (NYSE:MYOV)

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.

MYOV Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Previous Symbol
NASDAQ:MYOV
Fax
N/A
Employees
407
Year Founded
N/A

Company Calendar

Last Earnings
5/10/2022
Today
7/02/2022
Next Earnings (Estimated)
7/27/2022
Fiscal Year End
3/31/2023

Price Target and Rating

Average Stock Price Forecast
$16.67
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+28.6%
Consensus Rating
Hold
Rating Score (0-4)
2.33333333333333
Research Coverage
3 Analysts

Profitability

Net Income
$-205.98 million
Pretax Margin
-87.00%

Debt

Sales & Book Value

Annual Sales
$230.97 million
Book Value
($5.04) per share

Miscellaneous

Free Float
90,470,000
Market Cap
$1.24 billion
Optionable
Not Optionable
Beta
2.78














Myovant Sciences Frequently Asked Questions

Should I buy or sell Myovant Sciences stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Myovant Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYOV, but not buy additional shares or sell existing shares.
View analyst ratings for Myovant Sciences
or view top-rated stocks.

What is Myovant Sciences' stock price forecast for 2022?

3 Wall Street analysts have issued twelve-month price targets for Myovant Sciences' shares. Their MYOV stock forecasts range from $12.00 to $20.00. On average, they anticipate Myovant Sciences' share price to reach $16.67 in the next year. This suggests a possible upside of 28.6% from the stock's current price.
View analysts' price targets for Myovant Sciences
or view top-rated stocks among Wall Street analysts.

How has Myovant Sciences' stock performed in 2022?

Myovant Sciences' stock was trading at $15.57 on January 1st, 2022. Since then, MYOV shares have decreased by 16.8% and is now trading at $12.96.
View the best growth stocks for 2022 here
.

When is Myovant Sciences' next earnings date?

Myovant Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for Myovant Sciences
.

How were Myovant Sciences' earnings last quarter?

Myovant Sciences Ltd. (NYSE:MYOV) issued its earnings results on Tuesday, May, 10th. The company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by $0.08. The business had revenue of $57.57 million for the quarter, compared to analysts' expectations of $60.76 million.
View Myovant Sciences' earnings history
.

Who are Myovant Sciences' key executives?

Myovant Sciences' management team includes the following people:
  • Mr. David C. Marek, CEO & Director (Age 57, Pay $1.31M) (LinkedIn Profile)
  • Mr. Matthew Lang J.D., Gen. Counsel & Corp. Sec. (Age 46, Pay $1.03M) (LinkedIn Profile)
  • Mr. Uneek Mehra, Chief Financial & Bus. Officer
  • Mr. Albert Liao, Director of Corp. Communications
  • Mr. Bryan Selby, Sr. VP of Product Devel.
  • Dr. Juan Camilo Arjona Ferreira M.D., Chief Medical Officer (Age 52)
  • Dr. Teresa Perney Ph.D., Sr. VP of Regulatory Affairs & Quality Assurance
  • Dr. Andria Langenberg M.D., Head of Drug Safety & Pharmacovigilance (Age 65)
  • Mr. Jeffrey D. Nornhold, Sr. VP of Pharmaceutical Operations & Devel. (Age 56)
  • Ms. Lauren Merendino, Chief Commercial Officer (Age 47)

What other stocks do shareholders of Myovant Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Coty (COTY), Gilead Sciences (GILD), Micron Technology (MU), VBI Vaccines (VBIV), NVIDIA (NVDA) and Carnival Co. & (CCL).

When did Myovant Sciences IPO?

(MYOV) raised $176 million in an IPO on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

What is Myovant Sciences' stock symbol?

Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."

How do I buy shares of Myovant Sciences?

Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Myovant Sciences' stock price today?

One share of MYOV stock can currently be purchased for approximately $12.96.

How much money does Myovant Sciences make?

Myovant Sciences (NYSE:MYOV) has a market capitalization of $1.24 billion and generates $230.97 million in revenue each year. The company earns $-205.98 million in net income (profit) each year or ($2.210010) on an earnings per share basis.

How many employees does Myovant Sciences have?

Myovant Sciences employs 407 workers across the globe.

How can I contact Myovant Sciences?

Myovant Sciences' mailing address is 11-12 ST. JAMES SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The official website for Myovant Sciences is www.myovant.com. The company can be reached via phone at 442074003351 or via email at investors@myovant.com.

This page (NYSE:MYOV) was last updated on 7/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.